Syntara expands SNT-9465 skin scarring study

• SNT-9465 Phase 1b study expands to 30 participants
• Blinded study design maintained for robust dataset
• Top-line results expected in Q1 2027

Syntara Limited (ASX: SNT) announced an expansion of its Phase 1b study for SNT-9465, its second-generation topical pan-lysyl oxidase (pan-LOX) inhibitor, which is being evaluated for hypertrophic scars following sternotomy surgery. With recruitment of the initial 20-participant cohort nearing completion, Syntara has elected to expand the double-blind, placebo-controlled study to 30 participants to provide a larger and more robust dataset. The Skin Hospital in Sydney has been added as an additional clinical site to support timely recruitment. Top-line study results are now expected in Q1 2027. Syntara also provided an update on the exploratory investigator-initiated SATELLITE study evaluating SNT-6302, its first-generation topical pan-LOX inhibitor, in keloid scars. Six participants have completed the 12-week treatment period and remain in follow-up, with preliminary findings showing increased blood-vessel area density at Week 12.

Top-line results expected in Q1 2027

Syntara looks forward to evaluating whether the biological rationale for pan-LOX inhibition translates into an acceptable safety and tolerability profile and evidence of clinical activity in this study.